Carrie Lachance Buys 1,967 Shares of InfuSystem Holdings, Inc. (NYSE:INFU) Stock

InfuSystem Holdings, Inc. (NYSE:INFU - Get Free Report) COO Carrie Lachance bought 1,967 shares of the company's stock in a transaction dated Friday, May 16th. The shares were purchased at an average price of $6.10 per share, with a total value of $11,998.70. Following the transaction, the chief operating officer now owns 190,212 shares of the company's stock, valued at $1,160,293.20. The trade was a 1.04% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Carrie Lachance also recently made the following trade(s):

• On Thursday, May 15th, Carrie Lachance purchased 1,165 shares of InfuSystem stock. The stock was bought at an average price of $6.00 per share, for a total transaction of $6,990.00.

InfuSystem Stock Down 4.1%

INFU stock traded down $0.25 during mid-day trading on Thursday, hitting $5.80. 175,239 shares of the company were exchanged, compared to its average volume of 93,525. The company has a debt-to-equity ratio of 0.50, a quick ratio of 1.59 and a current ratio of 1.98. InfuSystem Holdings, Inc. has a 1-year low of $4.61 and a 1-year high of $9.97. The firm's 50 day simple moving average is $5.31 and its 200 day simple moving average is $7.12. The firm has a market cap of $121.89 million, a P/E ratio of 96.68 and a beta of 1.73.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on INFU. Wall Street Zen cut InfuSystem from a "strong-buy" rating to a "buy" rating in a research note on Wednesday, May 14th. Sidoti raised InfuSystem to a "strong-buy" rating in a research note on Tuesday, March 18th. Finally, B. Riley raised InfuSystem to a "strong-buy" rating in a research note on Thursday, May 8th.

Institutional Investors Weigh In On InfuSystem

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Barclays PLC boosted its stake in InfuSystem by 300.5% in the 3rd quarter. Barclays PLC now owns 28,597 shares of the company's stock worth $192,000 after purchasing an additional 21,457 shares during the period. JPMorgan Chase & Co. lifted its holdings in shares of InfuSystem by 74.1% in the third quarter. JPMorgan Chase & Co. now owns 15,556 shares of the company's stock valued at $104,000 after purchasing an additional 6,623 shares in the last quarter. Wells Fargo & Company MN lifted its holdings in shares of InfuSystem by 51.7% in the fourth quarter. Wells Fargo & Company MN now owns 9,286 shares of the company's stock valued at $78,000 after purchasing an additional 3,165 shares in the last quarter. First Eagle Investment Management LLC boosted its position in shares of InfuSystem by 25.9% during the fourth quarter. First Eagle Investment Management LLC now owns 908,371 shares of the company's stock worth $7,676,000 after buying an additional 186,668 shares during the period. Finally, Sei Investments Co. bought a new position in shares of InfuSystem during the fourth quarter worth about $90,000. 71.13% of the stock is currently owned by institutional investors and hedge funds.

About InfuSystem

InfuSystem Holdings, Inc, through its subsidiaries, provides infusion pumps, and related products and services in the United States and Canada. The company operates in two segments, Patient Services and Device Solutions. It supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology, infusion, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states.